tiprankstipranks
Trending News
More News >
BICO Group AB Class B (CLLKF)
:CLLKF

BICO Group AB Class B (CLLKF) Price & Analysis

Compare
35 Followers

CLLKF Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

<0.01%1.56%96.45%
Insiders
1.56% Other Institutional Investors
96.45% Public Companies and
Individual Investors

CLLKF FAQ

What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was $2.43 and its highest was $5.60 in the past 12 months.
    What is BICO Group AB Class B’s market cap?
    BICO Group AB Class B’s market cap is $236.42M.
      When is BICO Group AB Class B’s upcoming earnings report date?
      BICO Group AB Class B’s upcoming earnings report date is Apr 29, 2025 which is in 18 days.
        How were BICO Group AB Class B’s earnings last quarter?
        BICO Group AB Class B released its earnings results on Feb 19, 2025. The company reported $0.427 earnings per share for the quarter, beating the consensus estimate of -$0.023 by $0.45.
          Is BICO Group AB Class B overvalued?
          According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does BICO Group AB Class B pay dividends?
            BICO Group AB Class B does not currently pay dividends.
            What is BICO Group AB Class B’s EPS estimate?
            BICO Group AB Class B’s EPS estimate is -0.09.
              How many shares outstanding does BICO Group AB Class B have?
              BICO Group AB Class B has 69,074,900 shares outstanding.
                What happened to BICO Group AB Class B’s price movement after its last earnings report?
                BICO Group AB Class B reported an EPS of $0.427 in its last earnings report, beating expectations of -$0.023. Following the earnings report the stock price went up 13.714%.
                  Which hedge fund is a major shareholder of BICO Group AB Class B?
                  Currently, no hedge funds are holding shares in CLLKF
                  ---

                  Company Description

                  BICO Group AB Class B

                  BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
                  ---

                  CLLKF Company Deck

                  ---

                  CLLKF Earnings Call

                  Q4 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call reflects a challenging year for BICO with several operational improvements leading to a stronger EBITDA margin and a solid cash position. However, the company faced significant hurdles with negative sales growth, particularly in Lab Automation and the Chinese market. Despite these challenges, BICO is well-positioned with improved operational efficiencies and a strong cash flow, but the overall sales outlook remains cautious.Read More>
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  CellaVision AB
                  Paxman AB
                  Xvivo Perfusion AB
                  Humana AB
                  Xspray Pharma AB
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis